Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis

Journal Article · · Neurological Sciences

Not provided.

Research Organization:
Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
DOE Contract Number:
SC0014664
OSTI ID:
1981482
Journal Information:
Neurological Sciences, Vol. 43, Issue 3; ISSN 1590-1874
Publisher:
Springer
Country of Publication:
United States
Language:
English

References (34)

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies journal October 2021
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies journal January 2021
Immune determinants of COVID-19 disease presentation and severity journal January 2021
Diagnosis and Treatment of Multiple Sclerosis journal February 2021
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran journal August 2020
Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis journal February 2021
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab journal December 2021
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review journal May 2021
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? journal July 2021
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France journal July 2021
Immune response to vaccines is maintained in patients treated with dimethyl fumarate journal November 2017
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues journal April 2021
Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein journal January 2021
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis journal June 2021
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis journal September 2020
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis journal October 2021
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study journal November 2021
Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic journal January 2021
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments journal November 2020
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg journal December 2020
COVID-19 in multiple sclerosis patients and risk factors for severe infection journal November 2020
Multiple sclerosis management during the COVID-19 pandemic journal August 2020
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies journal November 2021
Adaptive immunity to SARS-CoV-2 and COVID-19 journal February 2021
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis journal November 2020
Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study journal July 2020
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response journal January 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies journal March 2021
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis journal December 2021
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients journal November 2020
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience journal April 2021
COVID-19 and the human innate immune system journal April 2021
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry journal May 2020
Collider bias undermines our understanding of COVID-19 disease risk and severity journal November 2020